ArticleBMC infectious diseases2026
Rising burden of Plasmodium vivax in Mizoram: an emerging threat to malaria elimination in Northeast India.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndia has made tremendous progress in malaria elimination efforts; however, several malaria pockets with high transmission remain that require continuous focus. The Northeast (NE) state of Mizoram, bordering Bangladesh and Myanmar, tops the list for disproportionately contributing to India's malaria burden. Considered a Plasmodium falciparum-endemic region, this study details the shift in malaria epidemiology from P. falciparum to P. vivax in Mizoram, complicating malaria elimination efforts in an already highly vulnerable setting.
methodsMalaria data for the NE states were obtained from the National Center for Vector Borne Disease Control, while aggregated health center-wise data for Mizoram's Mamit district (2021-2025) were obtained from the Office of the Chief Medical Officer, Mamit district, Mizoram. Spatiotemporal analyses of malaria cases and environmental variables were performed using ArcGIS 10.4 to identify disease trends, clustering, and high-risk areas.
resultsIn Mizoram, the steep shift in malaria incidence from P. falciparum to P. vivax was noticeable from 2022 onward; from 23% in 2021, P. vivax increased to 47% in 2024 and 42% in 2025. In 2020, Siaha-Mizoram's southern district bordering Myanmar-reported the first increase in P. vivax infections at the state level. In Mizoram's western district of Mamit, P. vivax contributed to 68% of the cases in 2025, and among children < 5 years, 86% of the infections were attributed to P. vivax. While P. falciparum transmission coincided with the monsoon season, P. vivax transmission was perennial.
conclusionThe recent surge in Mizoram's P. vivax cases appears to mirror the epidemiological shift from P. falciparum to P. vivax in bordering Myanmar. It is possible P. vivax parasites from Myanmar could have entered Mizoram through the southern districts of Siaha and Lawngtlai. As several studies in the last decade have reported chloroquine-resistant P. vivax infections in Myanmar, it is imperative that therapeutic efficacy studies are urgently carried out in Mizoram to ascertain the status of CQ-resistant parasites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.